Lexidrug vs Micromedex: Which Drug Database Fits Which Job

The short answer: Lexidrug (the product formerly called Lexicomp, now sold by Wolters Kluwer as UpToDate Lexidrug) and Micromedex (Merative) are the two dominant referenced drug databases in US hospitals, and they are more alike than different. Lexidrug tends to be preferred for speed at the point of care and for its tight integration with UpToDate; Micromedex tends to be preferred by pharmacy departments for depth, IV compatibility and toxicology content. Neither publishes a per-user list price for institutional use, so the real comparison happens in a procurement conversation. And neither is a prescribing decision-support tool: both are references you consult, not checks that run against your patient's regimen.

That last distinction is the one that decides most of these evaluations once someone names it out loud. Below is what actually separates the two products, where each one wins, and the question worth asking before you renew either.

What is the difference between Lexidrug and Micromedex?

Both are comprehensive, referenced drug information databases covering monographs, dosing, interactions, adverse effects, pregnancy and lactation data and pharmacokinetics. The difference is emphasis and shape.

Lexidrug is built to be answered from quickly. Its monographs are structured so that a clinician looking for a renal dose adjustment can land on it in a few taps, and its mobile app has historically been the strongest in the category. Because Wolters Kluwer owns both, Lexidrug content sits directly alongside UpToDate topics, so a clinician reading a UpToDate treatment recommendation can jump into the drug detail without leaving the interface. For an organization that already licenses UpToDate, that adjacency is a genuine workflow advantage rather than a marketing point.

Micromedex is built to be exhaustive. Its depth in toxicology and poison information is unmatched by anything else in routine use, it carries IV compatibility data through the Trissel's content, and it includes Red Book drug pricing data. Those modules are why drug information centers, poison control services and academic pharmacy departments standardize on it. A clinical pharmacist writing a formulary monograph or fielding a toxicology call is doing work that Micromedex was designed for and Lexidrug was not.

Which is better for the point of care?

For a prescriber at the bedside or in clinic, Lexidrug is generally the faster tool, and speed at that moment is most of the value. Micromedex answers more completely, but completeness is a liability when you have ninety seconds and a patient waiting. Pharmacists tend to report the opposite preference, because the questions they are answering justify the extra depth and they are usually not answering them mid-encounter.

This is why a lot of health systems end up licensing both, which is defensible when it is a deliberate decision and expensive when it is an accident. In practice it is usually an accident: the pharmacy department bought Micromedex, the medical staff bought UpToDate with Lexidrug attached, the EHR shipped with a third drug content vendor embedded in its order checking, and nobody has ever put the three contracts on the same page. Keeping a real inventory of what every team is actually paying for each month is unglamorous work that routinely finds five figures of redundant clinical content spend in a mid-sized system.

How much do Lexidrug and Micromedex cost?

Neither publishes an institutional list price, and anyone quoting you a confident per-user figure for either is guessing. Both are sold through a sales conversation because the deal includes user counts, module selection, contract term, authentication integration and often EHR embedding, none of which fits on a pricing page. We went through the structure of the Micromedex quote in detail in what Micromedex actually costs.

Wolters Kluwer does sell personal and small group subscriptions to UpToDate and UpToDate Lexidrug, so an individual clinician has a route in that Micromedex does not really offer. For reference on the parent product, UpToDate individual Pro subscriptions have listed at around $579 a year, which we broke down in the UpToDate cost breakdown. Check the Wolters Kluwer subscription page for the current Lexidrug personal figure rather than trusting any secondhand number, including this one.

The variables that move an institutional quote in either direction are the same for both vendors: how user count is defined (named, concurrent or full-time-equivalent produces very different totals from the same hospital), which modules are included, contract length, and whether the product is bundled. DynaMedex, sold through EBSCO, bundles DynaMed evidence summaries with Micromedex drug content, and if your organization pays for both separately that bundle is the first thing to price.

Lexidrug vs Micromedex: side by side

Which one has better drug interaction data?

Both are credible and both are referenced, and the honest answer is that comparative studies of interaction databases have repeatedly found meaningful disagreement between all of the major products, including these two. They differ on severity classification, on which interactions they include at all, and on how conservatively they phrase the recommended action. A combination flagged as contraindicated in one may appear as a moderate monitoring note in the other.

That disagreement is worth understanding rather than resolving. It means the choice between them is not a search for the correct database, because there isn't one. It means whichever you use, a flag is the beginning of a clinical judgment rather than the end of one, and the value of the reference is that it tells you what it thinks and shows you why, with the source attached, so you can decide.

The question that changes the evaluation

Both of these products answer questions you ask them. Neither of them notices anything on its own.

If a prescriber does not think to look up the patient's new antifungal against their existing simvastatin, no database in the world reports the interaction, because nobody queried it. The failure mode in real prescribing is almost never that the reference was wrong. It is that the lookup did not happen, at the end of a long clinic, on a medication list somebody else assembled. A reference and a check are different products solving different halves of the problem, and organizations frequently buy two of the first and none of the second.

That is where a decision-support layer does something a database cannot. Prescriber.io takes the actual regimen and returns the interaction flags with mechanism and cited source, the contraindication and allergy checks, the renal and hepatic dose considerations and guideline-based alternatives, in one card, without the clinician having to know in advance which question to ask. It is decision-support for licensed US clinicians, not a replacement for the reference and not autonomous prescribing. You review each flag, verify against official sources, and sign.

How to run the decision

A few practical moves, in the order that tends to work.

Separate the buyers before you compare products. Pharmacists and prescribers want different things, and a single evaluation committee that averages their preferences produces a decision neither group defends afterward. Ask each group what they actually opened last month, not what they think they need.

Pull utilization by module before requesting a renewal quote. Toxicology, IV compatibility and Red Book are the modules most often included by default and least often used across an entire organization, and the answer to "what happens to the price if we drop these" is sometimes surprising.

Price the bundles seriously. If you pay for UpToDate, Micromedex and DynaMed separately, at least two of those contracts have a bundled configuration that has never been quoted. We compared the underlying evidence products in UpToDate vs DynaMed and the wider field in our guide to the best clinical decision support software.

Finally, ask whether the prescribing checks are actually happening, separately from which reference you license. If the answer is that they happen when someone remembers to look, the reference comparison is the smaller of your two problems. Start with the drug interaction checker and see what one card looks like on a real regimen, or read our reference on CYP3A4 inhibitors and inducers, which is where most of the interactions either product will flag actually originate.